openPR Logo

Press Releases from ABA – Invest in Austria (1 total)

HORMONE REFRACTORY PROSTATE CANCER: NEW STUDIES IN AUSTRIA

Three clinical trials started at the Medical University of Vienna - Commissioned by multinational pharmaceutical firms Vienna, 29 March 2010 – The Medical University of Vienna has been commissioned by international pharmaceutical firms to conduct three clinical trials of the treatment of recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches comprise immunotherapy, hormone therapy and an augmented form of the current standard treatment with docetaxel. Team leader Prof. Dr. Michael Krainer